Tag: DNA-encoded libraries

Almirall + HitGen = novel oral compounds for AD

almirallshare-open innovation

Almirall, S.A. (ALM) and HitGen Ltd, a privately held biotechnology company established since 2012 in Chengdu, China, entered in a multi-target research collaboration to develop novel oral chemical entities (NCE) for patients suffering from moderate to severe atopic dermatitis.

The purpose of this strategic partnership is the identification of advanced hits, to be licensed by Almirall, using HitGen DNA-encoded library. HitGen has a robust platform with extensive libraries (nearly 400 billion compounds), and a strong track record of deal making, which makes it an excellent partner for Almirall.

Under the terms of the agreement, Almirall will provide reagents and material to screen the targets. HitGen will prosecute screening, hit ID, confirmation and early testing against the selected targets leveraging its proprietary unique DEL Screening platform.

Bhushan Hardas, M.D., MBA, Chief Scientific Officer of Almirall, commented that “this agreement keeps us on the track to achieve our goal of becoming a leading medical dermatology company. We look forward to collaborate with HitGen in identifying new molecules with the potential of becoming new treatment options for patients with atopic dermatitis“.

Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen, stated “we are delighted to enter this collaboration with Almirall, a leader in medical dermatology. This collaboration further emphasizes the role of HitGen in the rapidly developing field of DNA-encoded chemistry. We will work closely with Almirall’s scientists to develop novel oral chemical entities to address unmet medical needs in atopic dermatitis“.

About Almirall

Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying Science to provide medical solutions to patients and future generations. Our efforts are focused on fighting against skin health diseases and helping people feel and look their best. We support healthcare professionals by continuous improvement, bringing our innovative solutions where they are needed.

The company, founded almost 75 years ago with headquarters in Barcelona, is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has been key in value creation to society according to its commitment with to major shareholders and through its decision to help others, to understand their challenges and to use Science to provide solutions for real life. Total revenues in 2018 were 811 million euros. More than 1,800 employees are devoted to Science.

For more information, please visit almirall.com

About HitGen

HitGen is a rapidly growing biotech company with headquarters and main research facilities based in Chengdu, China and with a subsidiary in the USA. HitGen has established a platform for small molecule drug centred around the design, assembly and interrogation of DNA encoded chemical libraries (DELs). HitGen’s DELs contain nearly 400 billion novel, diverse, drug-like small molecule and macrocyclic compounds. These compounds are members of DELs synthe-sised from many hundreds of distinct chemical scaffolds, designed with tractable chemistry, and yielding proven results for the discovery of small molecule leads against precedented and un-precedented classes of biological targets. HitGen is collaborating with pharmaceutical, biotech, and chemical companies, foundations and research institutes in North America, Europe, Asia and Africa to discover and develop approaches for novel medicines and agrochemical solutions.

For more information, please visit www.hitgen.com or contact: Dr. Jin Li, Chairman & CEO, HitGen Ltd. Tel: +86 28 85197385 (8001)


Almirall + Mercachem = Looking for new cytokine blockers

AlmirallShare-Open Innovation

Almirall focuses on the improvement of inflammatory skin diseases. Almirall will support Mercachem’s cytokine blockers program to identify and develop novel small molecule therapeutics

The cytokine blockers program has its origin in the collaboration of Mercachem with Vipergen using its unique DNA-encoded library and BTE assay technology

Mercachem will receive an upfront payment and research fees to perform medicinal chemistry activities and progress the program. Mercachem is also eligible to receive further development milestones.

Almirall will fund Mercachem’s research in this area and perform any future pre- clinical, clinical, regulatory and commercial activities.

Barcelona, Spain, Nijmegen, The Netherlands, 21st December 2016 – Almirall S.A. and Mercachem announced today that they have entered into an exclusive discovery collaboration focusing on the development of oral cytokine blockers for the treatment of inflammatory skin diseases.

Under the terms of the agreement, Mercachem will perform iterative optimization campaigns towards the identification of oral cytokine blockers for Almirall to further develop. Almirall will fund Mercachem’s research in this area and perform any future pre- clinical, clinical, regulatory and commercial activities.

Mercachem will receive an upfront payment of EUR 1 million, research fees and is eligible to receive development milestone payments of up to in total maximum of EUR 5.5 million.

Thomas Eichholtz, CSO of Almirall, commented: “We are very happy to enter this research collaboration with Mercachem as it gives us access to groundbreaking technology that allows the identification of small molecules that can block protein-protein interactions. This opens up a whole new category of drug targets of great interest for our therapeutic area, dermatology. The collaboration is another example of our external innovation strategy”.

Gerhard Müller, Senior Vice President Medicinal Chemistry of Mercachem commented: “We  are  delighted  to partner  one of  our in-house innovation  projects with Almirall pursuing lead finding and optimization for a truly challenging target”. He further added: “In a previous joint collaboration with Vipergen we could demonstrate that deep sampling of DNA-encoded libraries employing Vipergen’s BTE assay technology delivered valuable hit classes with high medicinal chemistry utility to address difficult target systems”.


Media and Investor Relation’s Contact:

About Mercachem

Mercachem is a privately owned leading European contract research organization offering innovative chemistry, medicinal chemistry and early process research services and GMP production to accelerate the drug discovery and development process in a flexible and cost-effective way. Working for many pharmaceutical and biotech companies throughout the world, Mercachem is recognized for its high-quality products and services and its unprecedented problem solving capabilities.

More information on Mercachem can be found on the company website www.mercachem.com.

Business Development contact: Mercachem

Jan Schultz (Jan.schultz@mercachem.com)

Tel.: + (31) 24 3723300


About Almirall

Almirall is a global company based in Barcelona dedicated to providing valuable medicines and medical devices through its R&D, agreements and alliances. Our work covers the whole of the drug value chain. A consolidated growth allows us to devote our talent and efforts towards specialty areas and particularly to further grow as a leading Dermatology player. We are a specialist company, enabling us to accomplish the purpose of taking our innovative products wherever they are needed.

Founded in 1943, Almirall is listed on the Spanish Stock Exchange (ticker: ALM) and it has become a source of value creation for society due to its vision and the commitment of its long-standing major shareholders. In 2015, its revenues totaled 769 million euros and, with 1.800 employees, it has gradually built up a trusted presence across Europe, as well as in the USA.

For more information, please visit www.almirall.com.

Media contact: Cohn & Wolfe

Adriana Ibargüen (Adriana.ibarguen@cohnwolfe.com)/RebecaRocha (Rebeca.rocha@cohnwolfe.com)

Tel.: (+34) 91 531 42 67                                             

Investors & Corporate communication contact: Almirall

Pablo Divasson del Fraile

Tel (+34) 93 291 30 87



This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are “forward-looking statements”. These statements are based on currently available information and on best estimates and assumptions believed to be reasonable by the Companies. These statements involve risks and uncertainties beyond the Companies’ control. Therefore, actual results may differ materially from those stated by such forward-looking statements. The Companies expressly disclaim any obligation to review or update any forward-looking statements, targets or estimates contained in this document to reflect any change in the assumptions, events or circumstances on which such forward-looking statements are based unless so required by applicable law.